IDO1 and ovarian carcinoma: In addition, Inaba et al demonstrated that treatment with 1-MT plus paclitaxel synergistically prolonged mouse survival compared to treatment with paclitaxel alone in an IDO-overexpressing ovarian cancer peritoneal carcinomatosis model (26).